Page 112 - New epidemiological and PSMA-expression based paradigms in salivary gland tumors
P. 112
110
Chapter 6
21. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five Different Anti-Prostate- specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature. Cancer Res. 1999;59(13):3192-3198.
22. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Am Assoc Cancer Res. 1996;2(9):1445-1451.
23. Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem. 2013;13(8):951-962. doi:10.2174/1568026611313080008.
24. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Am Assoc Cancer Res. 1997;3(1):81-85.
25. Klein Nulent TJW, van Es RJJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis. Eur J Nucl Med Mol Imaging. June 2017. doi:10.1007/s00259-017-3737-x.
26. Lawhn-Heath C, Flavell RR, Glastonbury C, Hope TA, Behr SC. Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT. Clin Nucl Med. 2017;42(4):e218-e220. doi:10.1097/RLU.0000000000001569.
27. Lütje S, Heskamp S, Cornelissen AS, et al. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics. 2015;5(12):1388-1401. doi:10.7150/thno.13348.
28. Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA–PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226-235. doi:10.1038/nrurol.2016.26.
29. Wolf P, Freudenberg N, Bühler P, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70(5):562- 569. doi:10.1002/pros.21090.
30. Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound, CT MRI. 2010;31(6):496-505. doi:10.1053/j.sult.2010.10.001.
31. Różycki R. Diagnostic imaging of the nasolacrimal drainage system. Part I. Radiological anatomy of lacrimal pathways. Physiology of tear secretion and tear outflow. Med Sci Monit. 2014;20:628-638. doi:10.12659/MSM.890098.
32. Almståhl A, Alstad T, Fagerberg-Mohlin B, Carlén A FC. Explorative study on quality of life in relation to salivary secretion rate in patients with head and neck cancer treated with radiotherapy. Head Neck. 2016;38(5):782-791.
33. Jang JY, Pak KJ, Yi K-I, et al. Differential Prognostic Value of Metabolic Heterogeneity of Primary Tumor and Metastatic Lymph Nodes in Patients with Pharyngeal Cancer. Anticancer Res. 2017;37(10):5899- 5905. doi:10.21873/anticanres.12036.
34. Chan S-C, Cheng N-M, Hsieh C-H, et al. Multiparametric imaging using (18)F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. Oncotarget. 2017;8(37):62606-62621. doi:10.18632/oncotarget.15904.
35. Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med. 2015;56(8):1169-1176. doi:10.2967/jnumed.115.158550.
